Kintor Pharmaceutical: CEO Youzhi Tong Boosts Stake by 2.51 Million Shares Through Market Purchases and RSU Exercise

Bulletin Express05-28 21:03

Kintor Pharmaceutical Limited announced that Chairman, Executive Director and CEO Dr. Youzhi Tong increased his personal holding by 2.51 million shares, equal to 0.5039% of the company’s issued share capital.

Between 2 April and 28 May 2026, Dr. Tong acquired 1.26 million shares in the open market via his wholly owned KT International Investment Limited for approximately HK$3.32 million, translating to an average price of HK$2.63 per share and a trading range of HK$2.23–2.89 per share. In addition, he exercised 1.25 million restricted share units vested on 31 March 2026 at a cost of about HK$1.09 million.

Post-transaction, the company confirmed that its public float remains above the regulatory minimum. Dr. Tong cited confidence in Kintor Pharmaceutical’s clinical progress and commercialization of innovative topical drugs, particularly its anti-hair-loss and hair-regrowth pipeline, and indicated that further share purchases could be considered in accordance with applicable regulations.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1114902410?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-28 21:03","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1114902410","market":"us","top_or_hot":-1,"title":"Kintor Pharmaceutical: CEO Youzhi Tong Boosts Stake by 2.51 Million Shares Through Market Purchases and RSU Exercise","media":"Bulletin Express","content":"<p>Kintor Pharmaceutical Limited announced that Chairman, Executive Director and CEO Dr. Youzhi Tong increased his personal holding by 2.51 million shares, equal to 0.5039% of the company’s issued share capital.</p>\n<p>Between 2 April and 28 May 2026, Dr. Tong acquired 1.26 million shares in the open market via his wholly owned KT International Investment Limited for approximately HK$3.32 million, translating to an average price of HK$2.63 per share and a trading range of HK$2.23–2.89 per share. In addition, he exercised 1.25 million restricted share units vested on 31 March 2026 at a cost of about HK$1.09 million.</p>\n<p>Post-transaction, the company confirmed that its public float remains above the regulatory minimum. Dr. Tong cited confidence in Kintor Pharmaceutical’s clinical progress and commercialization of innovative topical drugs, particularly its anti-hair-loss and hair-regrowth pipeline, and indicated that further share purchases could be considered in accordance with applicable regulations.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Kintor Pharmaceutical: CEO Youzhi Tong Boosts Stake by 2.51 Million Shares Through Market Purchases and RSU Exercise</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nKintor Pharmaceutical: CEO Youzhi Tong Boosts Stake by 2.51 Million Shares Through Market Purchases and RSU Exercise\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-05-28 21:03</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Kintor Pharmaceutical Limited announced that Chairman, Executive Director and CEO Dr. Youzhi Tong increased his personal holding by 2.51 million shares, equal to 0.5039% of the company’s issued share capital.</p>\n<p>Between 2 April and 28 May 2026, Dr. Tong acquired 1.26 million shares in the open market via his wholly owned KT International Investment Limited for approximately HK$3.32 million, translating to an average price of HK$2.63 per share and a trading range of HK$2.23–2.89 per share. In addition, he exercised 1.25 million restricted share units vested on 31 March 2026 at a cost of about HK$1.09 million.</p>\n<p>Post-transaction, the company confirmed that its public float remains above the regulatory minimum. Dr. Tong cited confidence in Kintor Pharmaceutical’s clinical progress and commercialization of innovative topical drugs, particularly its anti-hair-loss and hair-regrowth pipeline, and indicated that further share purchases could be considered in accordance with applicable regulations.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"09939","symbol_name":"开拓药业-B","start_time":0,"source_url":"","article_id":"1114902410","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1114902410","pubTimestamp":1779973391,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Kintor Pharmaceutical Limited announced that Chairman, Executive Director and CEO Dr. Youzhi Tong increased his personal holding by 2.51 million shares, equal to 0.5039% of the company’s issued share...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"09939":"开拓药业-B"},"translate_title":"开拓药业：CEO童友志通过市场购买和受限制股份单位行权增持251万股","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"09939":1},"content_text":"Kintor Pharmaceutical Limited announced that Chairman, Executive Director and CEO Dr. Youzhi Tong increased his personal holding by 2.51 million shares, equal to 0.5039% of the company’s issued share capital.\nBetween 2 April and 28 May 2026, Dr. Tong acquired 1.26 million shares in the open market via his wholly owned KT International Investment Limited for approximately HK$3.32 million, translating to an average price of HK$2.63 per share and a trading range of HK$2.23–2.89 per share. In addition, he exercised 1.25 million restricted share units vested on 31 March 2026 at a cost of about HK$1.09 million.\nPost-transaction, the company confirmed that its public float remains above the regulatory minimum. Dr. Tong cited confidence in Kintor Pharmaceutical’s clinical progress and commercialization of innovative topical drugs, particularly its anti-hair-loss and hair-regrowth pipeline, and indicated that further share purchases could be considered in accordance with applicable regulations.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding,SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.3","shortVersion":"4.42.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1114902410","isCrawlerRequest":true}